Mellor R, Kearnes M, Lancaster K, McLauchlan L, Ritter A. Established tables and emergent huddles: exploring the processes of participation associated with the policy changes to opioid pharmacotherapy treatment in Australia in the context of COVID-19. Contemp Drug Probl. 2022 Sep 8;49(4):385-404. doi: 10.1177/00914509221123001
Lopez LR, Ahn J-H, Alves T, Arthur JC. Microenvironmental factors that shape bacterial metabolites in inflammatory bowel disease. Front Cell Infect Microbiol. 2022 Jul 15;12:934619. doi: 10.3389/fcimb.2022.934619
Colosia AD, Palencia R, Khan S. Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: a systematic literature review. Diabetes Metab Syndr Obes. 2013 Sep 17;6:327-38.
Curtis B, Hayes RP, Fehnel S, Zografos L. Assessing the effect of weight and weight loss in obese persons with type 2 diabetes. Diabetes Metab Syndr Obes. 2008 Oct 1;1:13-23.
Carroll I, Thomas JB, Dykstra LA, Granger AL, Allen RM, Howard JL, Pollard GT, Aceto MD, Harris LS. Pharmacological properties of JDTic: a novel kappa-opioid receptor antagonist. Eur J Pharmacol. 2004 Oct 6;501(1-3):111-9.